Catalent Gains European Commission Approval for Acquisition by Novo Holdings

• Catalent Inc. has received European Commission approval for its acquisition by Novo Holdings A/S.

• The transaction is expected to close by the end of 2024, subject to customary conditions and regulatory clearances.

Catalent, Inc., a global company specialising in the development and supply of advanced treatment solutions, has reached a critical milestone in its acquisition by Novo Holdings A/S, a prominent life sciences investment firm. The European Commission (EC) has granted unconditional approval for the transaction, moving both companies closer to finalising their strategic agreement.

Announced earlier this year, the acquisition signifies Novo Holdings’ commitment to supporting Catalent’s innovation-driven growth. “We are pleased to have received European Commission approval, which is a significant milestone toward completing our pending transaction with Novo Holdings,” said Alessandro Maselli, President and CEO of Catalent.

According to Jonathan Levy, Senior Partner at Novo Holdings, this development “brings us one step closer to delivering the benefits of this transaction.” He further emphasised Novo Holdings’ role in backing Catalent’s future initiatives, particularly its focus on delivering advanced solutions for customers and patients globally.

The transaction is set to close by the end of 2024, pending additional customary conditions and remaining regulatory approvals. Catalent’s shift to private ownership under Novo Holdings is expected to enable greater flexibility and resources to advance its mission in the healthcare sector.